Vivelle-Dot® Indications and Efficacy
4 Indications to Fit Your Different Patients
Vivelle-Dot has over 10 years of prescription history, providing patients with 4 approved indications:
- Treatment of moderate to severe vasomotor symptoms associated with menopause
- Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered
- Prevention of postmenopausal osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and nonestrogen medications should be carefully considered
- Treatment of hypoestrogenism due to hypogonadism, bilateral oophorectomy, or primary ovarian failure
Quick Onset of Action
Vivelle-Dot transdermal estrogen therapy (ET) can achieve therapeutic effect within 4 hours of first application*. That means your patients may begin to feel relief from symptoms associated with menopause, including moderate to severe hot flushes, night sweats and vaginal atrophy and dryness the same day that they begin treatment. When prescribed solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered.
Vivelle-Dot has also been shown to be effective for patients in preventing postmenopausal osteoporosis in doses as low as 0.025 mg/day.
Vivelle-Dot is an estrogen-only treatment. Patients who have vasomotor symptoms associated with menopause but still have a uterus can consider CombiPatch® (estradiol/norethindrone acetate transdermal system) treatment or should take progestin with Vivelle-Dot to protect against uterine cancer.